Detailed Information on Publication Record
2021
Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia
MANČÍKOVÁ, Veronika and Michal ŠMÍDABasic information
Original name
Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia
Authors
MANČÍKOVÁ, Veronika (703 Slovakia, belonging to the institution) and Michal ŠMÍDA (203 Czech Republic, guarantor, belonging to the institution)
Edition
International Journal of Molecular Sciences, Basel, Multidisciplinary Digital Publishing Institute, 2021, 1422-0067
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
10608 Biochemistry and molecular biology
Country of publisher
Switzerland
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 6.208
RIV identification code
RIV/00216224:14740/21:00123377
Organization unit
Central European Institute of Technology
UT WoS
000660178500001
Keywords in English
chimeric antigen receptor; immunotherapy; chronic lymphocytic leukemia; CD19
Tags
Tags
International impact, Reviewed
Změněno: 18/5/2022 13:27, Mgr. Pavla Foltynová, Ph.D.
Abstract
V originále
Chimeric antigen receptor (CAR) T-cell therapy has already achieved remarkable remissions in some difficult-to-treat patients with B-cell malignancies. Although the clinical experience in chronic lymphocytic leukemia (CLL) patients is limited, the proportion of remissions reached in this disease is clearly the lowest from the spectrum of B-cell tumors. In this review, we discuss the antigenic targets exploited in CLL CAR-T therapy, the determinants of favorable responses, as well as the mechanisms of treatment failure specific to this disease.
Links
| LQ1601, research and development project |
|